

# CITATION REPORT

List of articles citing

**Bile acids as regulators of hepatic lipid and glucose metabolism**

**DOI: 10.1159/000282091**

**Digestive Diseases, 2010, 28, 220-4.**

**Source:** <https://exaly.com/paper-pdf/49605169/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
235	Novel treatment modalities for nonalcoholic steatohepatitis. <b>2010</b> , 21, 668-75		55
234	Bile acids as regulators of hepatic lipid and glucose metabolism. <i>Digestive Diseases</i> , <b>2010</b> , 28, 220-4	3.2	219
233	Nuclear receptors as new perspective for the management of liver diseases. <b>2011</b> , 140, 1120-1125.e1-12		80
232	Sleeve gastrectomy in rats improves postprandial lipid clearance by reducing intestinal triglyceride secretion. <b>2011</b> , 141, 939-949.e1-4		78
231	Fermented <i>Camellia sinensis</i> , Fu Zhuan Tea, regulates hyperlipidemia and transcription factors involved in lipid catabolism. <b>2011</b> , 44, 2999-3005		65
230	The nuclear receptor FXR regulates hepatic transport and metabolism of glutamine and glutamate. <b>2011</b> , 1812, 1522-31		13
229	Abnormalities of lipid metabolism, gallstone disease and gallbladder function. <b>2011</b> , 6, 315-325		5
228	Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice. <b>2011</b> , 31, 52-64		46
227	Disorders of bile acid synthesis. <b>2011</b> , 34, 593-604		112
226	Synthesis of the 3-sulfates of N-acetylcysteine conjugated bile acids (BA-NACs) and their transient formation from BA-NACs and subsequent hydrolysis by a rat liver cytosolic fraction as shown by liquid chromatography/electrospray ionization-mass spectrometry. <b>2011</b> , 400, 2061-72		1
225	Evolution of genomic instability in diethylnitrosamine-induced hepatocarcinogenesis in mice. <b>2011</b> , 53, 895-904		41
224	Increased activation of the Wnt/ $\beta$ -catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. <b>2011</b> , 338, 12-21		100
223	Pleiotropic functions of the organic solute transporter Ost $\beta$ Ost $\alpha$ <i>Digestive Diseases</i> , <b>2011</b> , 29, 13-7	3.2	19
222	Targeting nuclear bile acid receptors for liver disease. <i>Digestive Diseases</i> , <b>2011</b> , 29, 98-102	3.2	22
221	Effect of ursodeoxycholic acid supplementation on growth, carcass characteristics, and meat quality of Wagyu heifers (Japanese Black cattle). <b>2011</b> , 89, 4221-6		6
220	Alterations in hepatic one-carbon metabolism and related pathways following a high-fat dietary intervention. <b>2011</b> , 43, 408-16		59
219	Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis. <b>2012</b> , 9, e1001338		111

218	Stimulatory effect of allantoin on imidazoline I <sub>2</sub> receptors in animal and cell line. <b>2012</b> , 44, 879-84	9
217	Evolution of substrate specificity for the bile salt transporter ASBT (SLC10A2). <b>2012</b> , 53, 1535-42	23
216	TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. <b>2012</b> , 2, 430	126
215	Hepatocyte-specific deletion of farnesoid X receptor delays but does not inhibit liver regeneration after partial hepatectomy in mice. <b>2012</b> , 56, 2344-52	73
214	Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease. <b>2012</b> , 47, 1257-66	42
213	A systems approach implicates nuclear receptor targeting in the Atp7b(-/-) mouse model of Wilson's disease. <b>2012</b> , 4, 660-8	30
212	FXR and PXR: potential therapeutic targets in cholestasis. <b>2012</b> , 130, 147-58	96
211	Specific bile acids inhibit hepatic fatty acid uptake in mice. <b>2012</b> , 56, 1300-10	47
210	Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. <b>2012</b> , 38, 55	28
209	NR1H4 analysis in patients with progressive familial intrahepatic cholestasis, drug-induced cholestasis or intrahepatic cholestasis of pregnancy unrelated to ATP8B1, ABCB11 and ABCB4 mutations. <b>2012</b> , 36, 569-73	17
208	The SLC10 carrier family: transport functions and molecular structure. <b>2012</b> , 70, 105-68	87
207	Farnesoid x receptor agonists: what they are and how they might be used in treating liver disease. <b>2012</b> , 14, 55-62	11
206	Cholecystectomy and NAFLD: does gallbladder removal have metabolic consequences?. <b>2013</b> , 108, 959-61	26
205	Cholesterol and male fertility: what about orphans and adopted?. <b>2013</b> , 368, 30-46	46
204	Role of bile acids in liver injury and regeneration following acetaminophen overdose. <b>2013</b> , 183, 1518-1526	49
203	Gut microbiota and non-alcoholic fatty liver disease: new insights. <b>2013</b> , 19, 338-48	157
202	CYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid. <b>2013</b> , 266, 245-53	43
201	Treatment of mouse liver slices with cholestatic hepatotoxicants results in down-regulation of Fxr and its target genes. <b>2013</b> , 6, 39	16

200	Proprotein convertases in high-density lipoprotein metabolism. <b>2013</b> , 1, 27	16
199	MicroRNA-33 in atherosclerosis etiology and pathophysiology. <b>2013</b> , 227, 201-8	35
198	Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. <b>2013</b> , 268, 132-40	110
197	Apolipoprotein E knockout as the basis for mouse models of dyslipidemia-induced neuropathy. <b>2013</b> , 239, 102-10	24
196	Nuclear receptors as drug targets in cholestatic liver diseases. <b>2013</b> , 17, 161-89	76
195	Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population. <b>2013</b> , 108, 952-8	77
194	Bile Acid Receptors and Liver Cancer. <b>2013</b> , 1, 29-35	53
193	Novel therapeutic targets for nonalcoholic fatty liver disease. <b>2013</b> , 17, 773-9	14
192	Clostridium scindens: a human gut microbe with a high potential to convert glucocorticoids into androgens. <b>2013</b> , 54, 2437-49	128
191	Fatty liver accompanies an increase in lactobacillus species in the hind gut of C57BL/6 mice fed a high-fat diet. <b>2013</b> , 143, 627-31	62
190	An association between post-meal bile acid response and bone resorption in normal subjects. <b>2013</b> , 50, 558-63	7
189	A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. <b>2013</b> , 36, 1859-64	172
188	Regulation of DDAH1 as a Potential Therapeutic Target for Treating Cardiovascular Diseases. <b>2013</b> , 2013, 619207	7
187	Role of nuclear receptors in lipid dysfunction and obesity-related diseases. <b>2013</b> , 41, 1-11	33
186	Roles for PI3K/AKT/PTEN Pathway in Cell Signaling of Nonalcoholic Fatty Liver Disease. <b>2013</b> , 2013, 472432	90
185	Adiponectin, bile acids, and burnt-out nonalcoholic steatohepatitis: new light on an old paradox. <b>2013</b> , 57, 2106-9	9
184	Toxic effects of dietary hydrolysed lipids: an in vivo study on fish larvae. <b>2013</b> , 109, 1071-81	5
183	The molecular pathogenesis of cholestasis in sepsis. <b>2013</b> , 5, 87-96	28

182	Association of cholecystectomy with metabolic syndrome in a Chinese population. <i>PLoS ONE</i> , <b>2014</b> , 9, e88189	3-7	24
181	Obesity, fatty liver disease and intestinal microbiota. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 16452-563	563	109
180	Metal Zn(II), Cu(II), Ni (II) complexes of ursodeoxycholic acid as putative anticancer agents. <b>2014</b> , 28, 543-551		4
179	Cystic fibrosis related liver disease--another black box in hepatology. <b>2014</b> , 15, 13529-49		37
178	Rate of steroid double-bond reduction catalysed by the human steroid 5 $\beta$ -reductase (AKR1D1) is sensitive to steroid structure: implications for steroid metabolism and bile acid synthesis. <b>2014</b> , 462, 163-71		12
177	ER stress and hepatic lipid metabolism. <b>2014</b> , 5, 112		77
176	Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism. <b>2014</b> , 275, 27-38		68
175	Ursodeoxycholic acid inhibits liver X receptor $\beta$ -mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE. <b>2014</b> , 289, 1079-91		31
174	Obesity and NAFLD: the role of bacteria and microbiota. <b>2014</b> , 18, 59-71		72
173	Bile metabolism and lithogenesis. <b>2014</b> , 94, 361-75		23
172	Intrahepatic cholestasis of pregnancy is associated with an increased risk of gestational diabetes. <b>2014</b> , 176, 80-5		67
171	Transcriptional dynamics of bile salt export pump during pregnancy: mechanisms and implications in intrahepatic cholestasis of pregnancy. <b>2014</b> , 60, 1993-2007		64
170	iTRAQ-based proteomics for studying the effects of dioscin against nonalcoholic fatty liver disease in rats. <b>2014</b> , 4, 30704		33
169	All-trans retinoic acid regulates hepatic bile acid homeostasis. <b>2014</b> , 91, 483-9		31
168	Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer. <b>2014</b> , 239, 1489-504		59
167	NHE1 deficiency in liver: implications for non-alcoholic fatty liver disease. <b>2014</b> , 450, 1027-31		13
166	A simple and accurate HPLC method for fecal bile acid profile in healthy and cirrhotic subjects: validation by GC-MS and LC-MS. <b>2014</b> , 55, 978-90		78
165	Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion. <b>2014</b> , 70, 667-74		15

164	Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. <b>2014</b> , 59, 1738-49		188
163	Factors associated with fibroblast growth factor 19 increment after oral glucose loading in patients who were previously admitted for coronary angiography. <b>2015</b> , 450, 237-42		3
162	Pathophysiological role of host microbiota in the development of obesity. <b>2016</b> , 15, 43		69
161	Paediatric non-alcoholic fatty liver disease: an overview. <b>2015</b> , 16, 393-405		38
160	Bile acid malabsorption in inflammatory bowel disease. <b>2015</b> , 21, 476-83		43
159	Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease. <b>2015</b> , 61, 85-90		31
158	Metabolic effects of cholecystectomy: gallbladder ablation increases basal metabolic rate through G-protein coupled bile acid receptor Gpbar1-dependent mechanisms in mice. <i>PLoS ONE</i> , <b>2015</b> , 10, e0118478	3.7	14
157	Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 6287-95	5.6	36
156	Role of FXR in $\beta$ cells of lean and obese mice. <b>2015</b> , 156, 1263-71		27
155	Persistent Fat Malabsorption in Cystic Fibrosis. <b>2015</b> , 373-381		0
154	Translational biomarkers of acetaminophen-induced acute liver injury. <b>2015</b> , 89, 1497-522		43
153	Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. <b>2015</b> , 1852, 1765-78		157
152	24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 871-8	13.4	46
151	Loss of Cyp8b1 improves glucose homeostasis by increasing GLP-1. <b>2015</b> , 64, 1168-79		60
150	Maternal circulating levels of irisin in intrahepatic cholestasis of pregnancy. <b>2016</b> , 29, 3483-7		4
149	Zonation of hepatic fatty acid metabolism - The diversity of its regulation and the benefit of modeling. <b>2015</b> , 1851, 641-56		46
148	Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <b>2015</b> , 90, 1233-46		142
147	Neuroendocrine adaptations to bariatric surgery. <b>2015</b> , 418 Pt 2, 143-52		33

146	Peroxisome Proliferator-Activated Receptor $\beta$ in Lipid Metabolism and Atherosclerosis. <b>2015</b> , 71, 171-203	40
145	Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders. <i>Digestive Diseases</i> , <b>2015</b> , 33, 433-9	3,2 31
144	Early Increases in Bile Acids Post Roux-en-Y Gastric Bypass Are Driven by Insulin-Sensitizing, Secondary Bile Acids. <b>2015</b> , 100, E1225-33	82
143	Estrogen and Estrogen Receptor- $\beta$ -Mediated Transrepression of Bile Salt Export Pump. <b>2015</b> , 29, 613-26	30
142	Caring for children with NAFLD and navigating their care into adulthood. <b>2015</b> , 12, 617-28	16
141	Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. <b>2015</b> , 47, 181-90	430
140	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. <b>2015</b> , 385, 956-65	1421
139	11 $\beta$ -Hydroxysteroid dehydrogenase 1: Regeneration of active glucocorticoids is only part of the story. <b>2015</b> , 151, 85-92	33
138	Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?. <b>2016</b> , 18, 439-43	46
137	Oleanolic, Ursolic, and Betulinic Acids as Food Supplements or Pharmaceutical Agents for Type 2 Diabetes: Promise or Illusion?. <b>2016</b> , 64, 2991-3008	88
136	Metabolomics of fecal samples: A practical consideration. <b>2016</b> , 57, 244-255	45
135	Effect of asymmetric dimethylarginine (ADMA) on heart failure development. <b>2016</b> , 54, 73-81	31
134	Future Treatments of NASH. <b>2016</b> , 15, 125-133	2
133	Longer-Term Physiological and Metabolic Effects of Gastric Bypass Surgery. <b>2016</b> , 16, 50	10
132	Gastrointestinal, Pancreatic, and Hepatobiliary Manifestations of Cystic Fibrosis. <b>2016</b> , 63, 679-98	19
131	Beneficial effects of voglibose administration on body weight and lipid metabolism via gastrointestinal bile acid modification. <b>2016</b> , 63, 691-702	10
130	Oleanolic Acid Improves Gut Atrophy Induced by Parenteral Nutrition. <b>2016</b> , 40, 67-72	15
129	Role of enterohepatic recirculation in drug disposition: cooperation and complications. <b>2016</b> , 48, 281-327	32

128	Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. <b>2016</b> , 36, 69-86	67
127	Gut Microbiota of Nonalcoholic Fatty Liver Disease. <b>2016</b> , 61, 1268-81	37
126	The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease. <b>2016</b> , 51, 808-18	29
125	The value of surrogate markers to monitor cholesterol absorption, synthesis and bioconversion to bile acids under lipid lowering therapies. <b>2017</b> , 169, 111-122	10
124	A Synthetic-Biology-Inspired Therapeutic Strategy for Targeting and Treating Hepatogenous Diabetes. <b>2017</b> , 25, 443-455	30
123	Anti-hyperlipidemic effects of Rhizoma Coptidis alkaloids are achieved through modulation of the enterohepatic circulation of bile acids and cross-talk between the gut microbiota and the liver. <b>2017</b> , 35, 205-215	8
122	Promotion of classic neutral bile acids synthesis pathway is responsible for cholesterol-lowering effect of Si-miao-yong-an decoction: Application of LC-MS/MS method to determine 6 major bile acids in rat liver and plasma. <b>2017</b> , 135, 167-175	17
121	Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway. <b>2017</b> , 91, 110-122	94
120	Farnesoid X receptor regulates SULT1E1 expression through inhibition of PGC1 $\beta$ binding to HNF4 $\beta$ . <b>2017</b> , 145, 202-209	14
119	Preserved Gut Microbial Diversity Accompanies Upregulation of TGR5 and Hepatobiliary Transporters in Bile Acid-Treated Animals Receiving Parenteral Nutrition. <b>2017</b> , 41, 198-207	13
118	G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice. <b>2017</b> , 65, 813-827	78
117	Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. <b>2017</b> , 4,	59
116	Antibiotic-Induced Alterations in Gut Microbiota Are Associated with Changes in Glucose Metabolism in Healthy Mice. <b>2017</b> , 8, 2306	66
115	The characteristics of small intestinal bacterial overgrowth in patients with gallstone diseases. <b>2018</b> , 33, 1477-1484	8
114	The influences of cholecystectomy on the circadian rhythms of bile acids as well as the enterohepatic transporters and enzymes systems in mice. <b>2018</b> , 35, 673-690	10
113	Nonalcoholic fatty liver disease, cholesterol gallstones, and cholecystectomy: new insights on a complex relationship. <b>2018</b> , 34, 90-96	17
112	Regulation of Hepatic Glucose Metabolism by FoxO Proteins, an Integrated Approach. <b>2018</b> , 127, 119-147	9
111	Non-estrogenic Xanthohumol Derivatives Mitigate Insulin Resistance and Cognitive Impairment in High-Fat Diet-induced Obese Mice. <b>2018</b> , 8, 613	31



110	Cholecystectomy as a risk factor of metabolic syndrome: from epidemiologic clues to biochemical mechanisms. <b>2018</b> , 98, 7-14	19
109	Cholecystectomy and risk of metabolic syndrome. <b>2018</b> , 53, 3-11	19
108	Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics. <b>2018</b> , 43, 269-280	14
107	NAFLD/NASH in patients with type 2 diabetes and related treatment options. <b>2018</b> , 41, 509-521	32
106	Chronic infusion of tauroolithocholate into the brain increases fat oxidation in mice. <b>2018</b> , 236, 85-97	10
105	Cholesterol oversynthesis markers define familial combined hyperlipidemia versus other genetic hypercholesterolemias independently of body weight. <b>2018</b> , 53, 48-57	10
104	New Pharmacological Opportunities for Betulinic Acid. <b>2018</b> , 84, 8-19	90
103	Fenugreek galactomannan and citrus pectin improve several parameters associated with glucose metabolism and modulate gut microbiota in mice. <b>2018</b> , 46, 134-142.e3	30
102	Jiangtang Xiaoke granule attenuates glucose metabolism disorder via regulating endoplasmic reticulum stress in the liver of type 2 diabetes mellitus mice. <b>2018</b> , 38, 570-578	1
101	Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes. <b>2018</b> , 46, S748-S754	18
100	Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study. <b>2018</b> , 7,	8
99	Anti-Fibrotic Therapies from Other Organs: What the Gut Can Learn from the Liver, Skin, Lung and Heart. <b>2018</b> , 347-385	
98	Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice. <b>2018</b> , 32, 3792-3802	24
97	Effects of the Artificial Sweetener Neotame on the Gut Microbiome and Fecal Metabolites in Mice. <b>2018</b> , 23,	41
96	Gender-divergent expression of lipid and bile acid metabolism-related genes in adult mice offspring of dams fed a high-fat diet. <i>Journal of Biosciences</i> , <b>2018</b> , 43, 329-337	2.3 9
95	Intrahepatic Cholestasis. <b>2018</b> , 445-464	
94	Molecular Basis of Liver Disease. <b>2018</b> , 417-456	
93	Gut Microbiota Influence Lipid and Glucose Metabolism, Energy Homeostasis and Inflammation Through Effects on Bile Acid Metabolism. <b>2018</b> , 107-134	1

92	Assessment of circulating betatrophin levels in intrahepatic cholestasis of pregnancy. <b>2019</b> , 32, 4067-4072	1
91	Semisynthetic bile acids: a new therapeutic option for metabolic syndrome. <b>2019</b> , 146, 104333	17
90	Effect of the aggregation state of bile salts on their transdermal absorption enhancing properties. <b>2019</b> , 54, 101333	3
89	Cholecystectomy versus central obesity or insulin resistance in relation to the risk of nonalcoholic fatty liver disease: the third US National Health and Nutrition Examination Survey. <b>2019</b> , 19, 95	7
88	Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease. <b>2019</b> , 63, e1900257	57
87	The alterations of bile acids in rats with high-fat diet/streptozotocin-induced type 2 diabetes and their negative effects on glucose metabolism. <b>2019</b> , 229, 80-92	12
86	Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions. <b>2019</b> , 1134, 33-58	1
85	Digestion, absorption, metabolism, and physiological effects of lactose. <b>2019</b> , 49-111	0
84	Permethrin and ivermectin modulate lipid metabolism in steatosis-induced HepG2 hepatocyte. <b>2019</b> , 125, 595-604	22
83	Identification of FDA-approved drugs targeting the Farnesoid X Receptor. <b>2019</b> , 9, 2193	11
82	Systemic bile acids induce insulin resistance in a TGR5-independent manner. <b>2019</b> , 316, E782-E793	4
81	Infantile Refsum Disease Associated with Hypobetalipoproteinemia. <b>2019</b> , 17, 210-212	
80	A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis. <b>2019</b> , 11, 159-178	17
79	Effects of diets with different energy and bile acids levels on growth performance and lipid metabolism in broilers. <b>2019</b> , 98, 887-895	19
78	Effect of a Common Genetic Variant (p.V444A) in the Bile Salt Export Pump on the Inhibition of Bile Acid Transport by Cholestatic Medications. <b>2019</b> , 16, 1406-1411	5
77	Constitutive Androstane Receptor Differentially Regulates Bile Acid Homeostasis in Mouse Models of Intrahepatic Cholestasis. <b>2019</b> , 3, 147-159	4
76	Betulin and its derivatives as novel compounds with different pharmacological effects. <b>2020</b> , 38, 107409	73
75	Unconjugated and secondary bile acid profiles in response to higher-fat, lower-carbohydrate diet and associated with related gut microbiota: A 6-month randomized controlled-feeding trial. <b>2020</b> , 39, 395-404	27

74	A human-like bile acid pool induced by deletion of hepatic modulates effects of FXR activation in mice. <b>2020</b> , 61, 291-305		52
73	Gluc-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology. <b>2020</b> , 105,		5
72	Identification of isotschimgine as a novel farnesoid X receptor agonist with potency for the treatment of obesity in mice. <b>2020</b> , 521, 639-645		7
71	Dietary bile acids regulate the hepatic lipid homeostasis in tiger puffer fed normal or high-lipid diets. <b>2020</b> , 519, 734935		19
70	In-silico therapeutic investigations of arjunic acid and arjungenin as an FXR agonist and validation in 3T3-L1 adipocytes. <b>2020</b> , 84, 107163		0
69	Growth performance, immunity and intestinal microbiota of swamp eel ( <i>Monopterus albus</i> ) fed a diet supplemented with house fly larvae ( <i>Musca domestica</i> ). <b>2020</b> , 26, 693-704		11
68	Dietary supplementation of plant essential oil improves growth performance, intestinal morphology and health in weaned pigs. <b>2020</b> , 104, 579-589		3
67	Increased circulating total bile acid levels were associated with organ failure in patients with acute pancreatitis. <b>2020</b> , 20, 222		2
66	Cholecystectomy as a risk factor for non-alcoholic fatty liver disease development. <b>2020</b> , 22, 1513-1520		3
65	Heterozygous knockout of Bile salt export pump ameliorates liver steatosis in mice fed a high-fat diet. <i>PLoS ONE</i> , <b>2020</b> , 15, e0234750	3-7	5
64	Connecting the Dots Between Inflammatory Bowel Disease and Metabolic Syndrome: A Focus on Gut-Derived Metabolites. <b>2020</b> , 12,		15
63	Development and validation of an ambulatory piglet model for short bowel syndrome with ileo-colonic anastomosis. <b>2020</b> , 245, 1049-1057		2
62	<i>Pulsatilla chinensis</i> saponins cause liver injury through interfering ceramide/sphingomyelin balance that promotes lipid metabolism dysregulation and apoptosis. <b>2020</b> , 76, 153265		14
61	The road ahead for health and lifespan interventions. <b>2020</b> , 59, 101037		48
60	Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis. <b>2020</b> , 9,		29
59	Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. <b>2020</b> , 318, G554-G573		54
58	RNA Profiling Analysis of the Serum Exosomes Derived from Patients with Chronic Hepatitis and Acute-on-chronic Liver Failure Caused By HBV. <b>2020</b> , 10, 1528		2
57	Differential Metabolomic Analysis of Liver Tissues from Rat Models of Parenteral Nutrition-Associated Liver Disease. <b>2020</b> , 2020, 9156359		3

56	Role of n-3 Fatty Acids on Bile Acid Metabolism and Transport in Dyslipidemia: A Review. <b>2021</b> , 56, 125-139	0
55	Metabolomics analysis delineates the therapeutic effects of Huangqi decoction and astragalosides on <i>Ehaphthylisothiocyanate</i> (ANIT)-induced cholestasis in rats. <b>2021</b> , 268, 113658	4
54	Effect of Gender and Various Diets on Bile Acid Profile and Related Genes in Mice. <b>2021</b> , 49, 62-71	1
53	Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?. <b>2021</b> , 15, 51-64	3
52	Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis. <b>2021</b> , 6, 60	2
51	Bile Acid Toxicity and Protein Kinases. <b>2021</b> , 1275, 229-258	1
50	Cardiometabolic risks and atherosclerotic disease in ApoE knockout mice: Effect of spinal cord injury and Salsalate anti-inflammatory pharmacotherapy. <i>PLoS ONE</i> , <b>2021</b> , 16, e0246601	3-7 0
49	Finger Citron Extract Ameliorates Glycolipid Metabolism and Inflammation by Regulating GLP-1 Secretion via TGR5 Receptors in Obese Rats. <b>2021</b> , 2021, 6623379	0
48	The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease. <b>2021</b> , 10,	3
47	Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. <b>2021</b> , 1, 4-52	31
46	Xanthohumol ameliorates Diet-Induced Liver Dysfunction via Farnesoid X Receptor-Dependent and Independent Signaling. <b>2021</b> , 12, 643857	6
45	Gender and gut microbiota composition determine hepatic bile acid, metabolic and inflammatory response to a single fast-food meal in healthy adults. <b>2021</b> , 40, 2609-2619	2
44	Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents. <b>2021</b> , 8, 700058	6
43	Bile acid-induced tissue factor activity in hepatocytes correlates with activation of farnesoid X receptor. <b>2021</b> , 101, 1394-1402	3
42	Anti-TNF $\alpha$ treatment in Crohn's disease: Impact on hepatic steatosis, gut-derived hormones and metabolic status. <b>2021</b> , 41, 2646-2658	0
41	Cholecystectomy as a risk factor for metabolic dysfunction-associated fatty liver disease: unveiling the metabolic and chronobiologic clues behind the bile acid enterohepatic circulation. <b>2021</b> , 77, 497-510	3
40	Preconception insulin resistance and neonatal birth weight in women with obesity: role of bile acids. <b>2021</b> , 43, 931-939	0
39	Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy. <b>2021</b> , 12, 711217	1

38	Gut Microbiota in Adipose Tissue Dysfunction Induced Cardiovascular Disease: Role as a Metabolic Organ. <b>2021</b> , 12, 749125		2
37	Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease. <b>2021</b> , 12, 715506		13
36	Metabolomics as a Truly Translational Tool for Precision Medicine. <b>2021</b> , 40, 413-426		4
35	Role of ursodeoxycholic acid on maternal serum bile acids and perinatal outcomes in intrahepatic cholestasis of pregnancy. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> , 33, 571-576	2.2	4
34	The green tea modulates large intestinal microbiome and exo/endogenous metabolome altered through chronic UVB-exposure. <i>PLoS ONE</i> , <b>2017</b> , 12, e0187154	3.7	19
33	Evolving roles of circadian rhythms in liver homeostasis and pathology. <i>Oncotarget</i> , <b>2016</b> , 7, 8625-39	3.3	20
32	Intrahepatic cholestasis of pregnancy is associated with an increased risk of gestational diabetes and preeclampsia. <i>Annals of Translational Medicine</i> , <b>2020</b> , 8, 1574	3.2	10
31	Bile acids, nuclear receptors and cytochrome P450. <i>Physiological Research</i> , <b>2016</b> , 65, S427-S440	2.1	16
30	Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 13493-500	5.6	26
29	Vitamin E Therapy in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Clinical Medicine</i> , <b>2014</b> , 05, 87-92	0.3	3
28	Bile acids induce apoptosis selectively in androgen-dependent and -independent prostate cancer cells. <i>PeerJ</i> , <b>2013</b> , 1, e122	3.1	55
27	Primary Sclerosing Cholangitis (PSC). <b>2014</b> , 301-316		
26	THE ROLE OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN THE PATHOGENESIS OF HYPERLIPIDEMIA. <i>Wiadomości Lekarskie</i> , <b>2019</b> , 72, 645-649	0.3	0
25	Activation of GLP-1 and Glucagon Receptors Regulates Bile Homeostasis Independent of Thyroid Hormone. <i>Current Molecular Pharmacology</i> , <b>2019</b> , 12, 139-146	3.7	1
24	Alcoholic liver disease. <i>Medical Alphabet</i> , <b>2020</b> , 25-32	0.3	
23	The effect of Corvitin on the content of bile acids in the liver of rats under conditions of chronic social stress. <i>Regulatory Mechanisms in Biosystems</i> , <b>2021</b> , 12, 419-424	0.7	
22	Immobilization of bile acid enzymes onto activated amino-ethyl cellulose and polyvinyl alcohol membranes. <i>Indian Journal of Clinical Anatomy and Physiology</i> , <b>2020</b> , 7, 292-295	0.2	
21	Non-alcoholic fatty liver disease, diet and gut microbiota. <i>EXCLI Journal</i> , <b>2014</b> , 13, 461-90	2.4	14

20	Bile Acid and Cholesterol Metabolism in Atherosclerotic Cardiovascular Disease and Therapy. <i>Cardiology Plus</i> , <b>2020</b> , 5, 159-170	0.3	
19	Dietary bile acids reduce liver lipid deposition via activating farnesoid X receptor, and improve gut health by regulating gut microbiota in Chinese perch ( <i>Siniperca chuatsi</i> ).. <i>Fish and Shellfish Immunology</i> , <b>2022</b> , 121, 265-275	4.3	0
18	Gender-divergent expression of lipid and bile acid metabolism related genes in adult mice offspring of dams fed a high-fat diet. <i>Journal of Biosciences</i> , <b>2018</b> , 43, 329-337	2.3	5
17	Newer variants of progressive familial intrahepatic cholestasis.. <i>World Journal of Hepatology</i> , <b>2021</b> , 13, 2024-2038	3.4	0
16	The Covert Surge: Murine Bile Acid Levels Are Associated With Pruritus in Pediatric Autoimmune Sclerosing Cholangitis. <i>Frontiers in Pediatrics</i> , <b>2022</b> , 10,	3.4	
15	Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease □ novel insights into cellular communication circuits. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	6
14	Effects of Dietary Inclusion of β-Hydroxy-β-Methylbutyrate on Growth Performance, Fat Deposition, Bile Acid Metabolism, and Gut Microbiota Function in High-Fat and High-Cholesterol Diet-Challenged Layer Chickens. <b>2022</b> , 44, 3413-3427		
13	Non-alcoholic fatty liver disease and cardiovascular pathology: features of patient management on a clinical example. <b>2022</b> , 290-297		0
12	The critical role of gut microbiota in obesity. 13,		3
11	Gut□Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome. <b>2022</b> , 11, 1622		0
10	Cognitive effects of Xanthohumol in wild-type and mutant mice lacking FXR in the intestine or liver on a high-fat diet.		0
9	Study on the mechanism of cholic acid derivatives in Traditional Chinese Medicine based on the regulation of gene expression. <b>2022</b> ,		0
8	Cystic fibrosis rabbits develop spontaneous hepatobiliary lesions and CFLD-like phenotypes.		0
7	The regulatory effects of second-generation antipsychotics on lipid metabolism: Potential mechanisms mediated by the gut microbiota and therapeutic implications. 14,		1
6	Spatiotemporal Metabolic Liver Zonation and Consequences on Pathophysiology. <b>2023</b> , 18, 439-466		0
5	Nonalcoholic fatty liver disease. <b>2023</b> , 83-97		0
4	Is microRNA-33 an Appropriate Target in the Treatment of Atherosclerosis?. <b>2023</b> , 15, 902		1
3	Copper-mediated shifts in transcriptomic responses of intestines in <i>Bufo gargarizans</i> tadpoles to lead stress. <b>2023</b> , 30, 50144-50161		0

- 2 Kröpel-like factor 15 in liver diseases: Insights into metabolic reprogramming. 14, ○
- 1 Bile Acids. **2023**, 509-529 ○